Western States Node

Principal Investigators:
P. Todd Korthuis, MD, MPH [email]
Professor of Medicine
Oregon Health & Science University
3181 SW Sam Jackson Park Road, L475
Portland, OR 97239-3098

Keith Humphreys, PhD [email]
Professor, Department of Psychiatry
Stanford University
401 N. Quarry Road, Room C-305
Stanford, CA 94305-5717

Related Resources

Node Facebook page
Node Twitter feed
NIDA web site

The Western States Node was established in 2010, combining into a single node both the Regional Research and Training Centers and the Community Treatment Programs of the original CTN nodes in Oregon/Hawaii and California/Arizona, with an additional CTP from Colorado.

Grantee Institutions: Oregon Health & Science University and Stanford University

Protocol Involvement

• CTN-0002: Buprenorphine/Naloxone versus Clonidine for Outpatient Opiate Detoxification
• CTN-0003: Suboxone (Buprenorphine / Naloxone) Taper: A Comparison of Taper Schedules
• CTN-0005: MI (Motivational Interviewing) to Improve Treatment Engagement and Outcome in Subjects Seeking Treatment for Substance Abuse
• CTN-0014: Brief Strategic Family Therapy for Adolescent Drug Abusers
• CTN-0017: HIV and HCV Intervention in Drug Treatment Settings
• CTN-0018: Reducing HIV/STD Risk Behaviors: A Research Study for Men in Drug Abuse Treatment
• CTN-0020: Job Seekers Training for Patients with Drug Dependence
• CTN-0021: Motivational Enhancement Treatment to Improve Treatment Engagement and Outcome for Spanish-Speaking Individuals Seeking Treatment for Substance Abuse
• CTN-0027: Starting Treatment with Agonist Replacement Therapies (START)
• CTN-0029: A Pilot Study of Osmotic-Release Methylphenidate in Initiating and Maintaining Abstinence in Smokers with ADHD
• CTN-0030-A-1: Collection of Economic Data for the Prescription Opioid Addiction Treatment Study
• CTN-0030: Prescription Opiate Abuse Treatment Study (POATS)
• CTN-0031-A-1: An Evaluation of Neurocognitive Function, Oxidative Damage, and Their Association with Treatment Outcomes in Methamphetamine and Cocaine Abusers
• CTN-0031-A-3: Organizational and Practitioner Influences on Implementation of STAGE-12
• CTN-0031: Stimulant Abuser Groups to Engage in 12-Step (STAGE-12): Evaluation of a Combined Individual-Group Intervention to Reduce Stimulant and Other Drug Use by Increasing 12-Step Involvement
• CTN-0032-A-1: Economic Analysis of HIV Rapid Testing in Drug Abuse Treatment Programs
• CTN-0032: HIV Rapid Testing and Counseling
• CTN-0033-Ot-1: Methamphetamine Use Among American Indians
• CTN-0033-Ot-5: The Choctaw Nation Methamphetamine Data Needs Project
• CTN-0035-Ot: Access to HIV and Hepatitis Screening and Care Among Ethnic Minority Drug Users In and Out of Drug Treatment
• CTN-0037-A-1: Site Influences on Treatment Effects – Exercise as a Treatment for Substance Use Disorders
• CTN-0038-Ot: Barriers to Substance Abuse Treatment Among Asian Americans and Pacific Islanders
• CTN-0043-S: Substance Abuse Treatment Outcomes in Racial/Ethnic Minority Populations
• CTN-0044-A-1: Site Influences on Treatment Effects – Web-Delivery of Evidence-Based, Psychosocial Treatment for Substance Use Disorders
• CTN-0044-A-2: Acceptability of a Web-delivered, Evidence-based, Psychosocial Intervention among Individuals with Substance Use Disorders who Identify as American Indian/Alaska Native
• CTN-0044-A-3: Acceptability of a Web-delivered, Evidence-based, Psychosocial Intervention among Individuals with Substance Use Disorders who Identify as American Indian/Alaska Native
• CTN-0044: Web-Delivery of Evidence-Based, Psychosocial Treatment for Substance Use Disorders
• CTN-0046-A-1: Site Influences on Treatment Effects – Smoking Cessation and Stimulant Treatment (S-CAST): Evaluation of the Impact of Concurrent Outpatient Smoking Cessation and Stimulant Treatment on Stimulant-Dependent Outcome
• CTN-0046: Smoking Cessation and Stimulant Treatment (S-CAST): Evaluation of the Impact of Concurrent Outpatient Smoking Cessation and Stimulant Treatment on Stimulant Dependence
• CTN-0047-A-1: Site Influences on Treatment Effects – Screening, Motivational Assessment, Referral, and Treatment in Emergency Departments (SMART-ED)
• CTN-0048-A-1: Pharmacogenetics of Buprenorphine/Naltrexone for Cocaine Dependence in the CURB Study
• CTN-0048: Cocaine Use Reduction with Buprenorphine (CURB)
• CTN-0050: Long-Term Follow-Up of START Patients
• CTN-0053: Achieving Cannabis Cessation — Evaluating N-Acetylcysteine Treatment (ACCENT)
• CTN-0055: Comparing Treatments for HIV-Positive Opioid Users in an Integrated Care Effectiveness Study (CHOICES)
• CTN-0066-Ot: Opioid Use Disorders in Primary Care Settings: Linking EHRs with PDMP and National Death Index Data Systems
• CTN-0067: Comparing Treatments for HIV-Positive Opioid Users in an Integrated Care Effectiveness Study (CHOICES): Scale-Up
• CTN-0068: Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder
• CTN-0080: Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs): A Pragmatic Randomized Trial Comparing Two Buprenorphine Formulations (NIH HEAL Initiative)
• CTN-0085: Selection Bias-Free Estimation of the Impact of Drug-focused Twelve Step Mutual Help Groups Using the VA Database
• CTN-0086: Inpatient versus Outpatient Treatment Outcomes for People with Opioid Use Disorder
• CTN-0098: Exemplar Hospital Initiation Trial to Enhance Treatment Engagement (EXHIT ENTRE)
• CTN-0101: Subthreshold Opioid Use Disorder Prevention (STOP) Trial
• CTN-0118: Examining the COVID-19 Public Health Emergency on Policy, Substance Use Disorder, Treatment and Resilience among American Indian and Alaska Native Communities
• CTN-0125: Integrative Data Analysis of CTN Studies to Examine the Impact of Psychosocial Treatments for Black People who use Cocaine
• CTN-0131: Office-Based Methadone versus Buprenorphine to Address Retention in Medication for Opioid Use Disorder Treatment – A Randomized Pragmatic Hybrid Effectiveness/Implementation Trial
• CTN-0149: Trajectories of Secondary Outcomes in CTN Trials